Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
CYTK Stock Chart & Stats
$62.72
-$0.99(-2.05%)
At close: 4:00 PM EST
$62.72
-$0.99(-2.05%)
Day’s Range― - ―
52-Week Range$29.31 - $69.33
Previous CloseN/A
Volume107.14K
Average Volume (3M)1.80M
Market Cap
$7.67B
Enterprise Value$6.83B
Total Cash (Recent Filing)$962.53M
Total Debt (Recent Filing)$1.20B
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Mar 04, 2026EPS Estimate
-1.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.55
Shares Outstanding122,264,930
10 Day Avg. Volume1,843,926
30 Day Avg. Volume1,802,257
Financial Highlights & Ratios
PEG Ratio2.56
Price to Book (P/B)-38.91
Price to Sales (P/S)285.13
P/FCF Ratio-13.18
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue78.26
Enterprise Value/Gross Profit-61.37
Enterprise Value/Ebitda-10.56
Forecast
1Y Price Target
$88.00Price Target Upside40.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial OutlookFDA approval of Myqorzo for symptomatic obstructive hypertrophic cardiomyopathy positively impacts its commercial outlook.
FDA ApprovalCytokinetics announced FDA approval of MYQORZO with a differentiated label featuring a straightforward dosing table and a tailored, manageable REMS program.
Market PositioningMYQORZO requires substantially fewer echocardiograms and patient monitoring forms compared to CAMZYOS, offering greater dosing flexibility.
Bears Say
Cytokinetics News
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $29.31 and its highest was $69.33 in the past 12 months.
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is $7.67B.
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Mar 04, 2026 which is in 70 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Nov 05, 2025. The company reported -$2.55 earnings per share for the quarter, missing the consensus estimate of -$1.571 by -$0.979.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.55.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 122,264,930 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$2.55 in its last earnings report, missing expectations of -$1.571. Following the earnings report the stock price went up 1.875%.
Which hedge fund is a major shareholder of Cytokinetics?
Currently, no hedge funds are holding shares in CYTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cytokinetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$88.00 (40.31% Upside)
$88.00 (40.31% Upside)
Blogger Sentiment
Bullish
CYTK Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days >0.1%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.03%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics to treat debilitating diseases in the fields of muscle biology and neuromuscular function. The company operates primarily in the biotechnology sector and is dedicated to advancing innovative treatments for heart failure, cancer, and other conditions that affect muscle strength and function. Its core products include various drug candidates targeting muscle contractility and function, with a strong emphasis on addressing unmet medical needs in the cardiovascular and neuromuscular arenas.
CYTK Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress towards the approval and commercial readiness of aficamten, supported by strong clinical trial results and a solid financial position. However, increased net loss and pending regulatory approvals present challenges.View all CYTK earnings summariesCYTK Stock 12 Month Forecast
Average Price Target
$88.00
▲(40.31% Upside)
Technical Analysis
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Avidity Biosciences
―
Nuvalent
―
Ownership Overview
Currently, No data available
---